News

More Stage I cancers were diagnosed after the passage of the Affordable Care Act (ACA), also known as Obamacare, within five screenable disease types: colorectal cancer, female breast cancer, cervical cancer, lung cancer, and prostate cancer).

The FDA has granted approval to pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

The human papillomavirus (HPV) vaccine has reduced the prevalence of high-risk oral HPV infections by 88& in young adults that have had at least 1 dose of the vaccine.

Eating tree nuts may improve overall survival and reduce the risk of recurrence in patients with colon cancer.

A recent analysis showed that many women within the recommended age for routine screening are not up to date on Pap tests.

A recent study has found that, when it comes to physical activity recommendations, there is a disparity between what patients want and what their providers do.

Researchers found that tai chi chih, including guided movement and meditation, may be helpful in reducing insomnia experienced by breast cancer survivors.

For asymptomatic adults, the US Preventive Services Task Force (USPSTF) recommends against screening for thyroid cancer.

The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for use in combination with pemetrexed plus carboplatin as a frontline treatment for patients with non-small cell lung cancer (NSCLC).

Expert Oncology Nurses to Lead Inaugural Conference.

The FDA has approved the co-packaging of oral medication ribociclib and letrozole, used to treat HR-positive, HER2-negative advanced breast cancer in postmenopausal women.

The FDA has granted accelerated approval to avelumab (Bavencio) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

At the 2017 ONS Annual Congress, nurses from John Hopkins Sidney Kimmel Cancer Center reported on their study involving vincristine infused via minibag infusions.

The revised American Health Care Act has passed through the House of Representatives.

At the 2017 Community Oncology Alliance annual conference, panelists discussed techniques to encourage improved adherence in patients on oral oncology medication.

ASCO has updated their guidance on the use of second-line hormonal therapy for chemotherapy-naive patients with castration-resistant prostrate cancer (CRPC).

A recent trial is evaluating a new drug to treat cachexia, testing its efficacy in dogs currently.

The FDA has granted accelerated approval for the PD-L1 inhibitor durvalumab for the treatment of locally advanced or metastatic urothelial carcinoma.

Seven professional organizations came together to issue a new position statment on recommendations for treating patients with aromatase-inhibitor-related bone loss (AIBL).

The FDA has granted accelerated approval to brigatinib for patients with metastatic ALK-positive non-small cell lung cancer (NSCLC) resistant to prior crizotinib (Xalkori).

A recent study indicates that the use of bilateral mastectomy to treat women with ductal carcinoma in situ is unnecessary.

The FDA has approved midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukemia.

A recent study has found correlations between common comorbidities (hypertension, heart disease, diabetes, etc) and ovarian cancer.

The FDA has approved regorafenib as a second-line treatment for patients with unresectable hepatocellular carcinoma, who had previously received sorafenib.

A recent study evaluated the effect of red light on hair growth in women with breast cancer.

Second primary cancers that occur in pediatric, adolescent and young adult (AYA) patients are deadlier than those that occur in older patients.

The FDA issued 14 warning letters and 4 online adviseries to a number of companies selling products which claim to prevent, diagnose, treat, mitigate or cure cancer without FDA approval.

While patients with stage III or IV melanoma who received a higher dose of ipilimumab did live longer than those on a lower dose, there was also greater toxicity.

For patients with hepatocellular carcinoma (HCC) who have progressed on sorafenib, regorafenib has shown to be an effective second-line treatment. The FDA has granted the agent a priority review